MCID: OVR013
MIFTS: 33

Ovarian Mucinous Cystadenocarcinoma

Categories: Cancer diseases, Endocrine diseases, Reproductive diseases

Aliases & Classifications for Ovarian Mucinous Cystadenocarcinoma

MalaCards integrated aliases for Ovarian Mucinous Cystadenocarcinoma:

Name: Ovarian Mucinous Cystadenocarcinoma 12 55 15
Mucinous Cystadenocarcinoma of Ovary 12 73

Classifications:



External Ids:

Disease Ontology 12 DOID:3604
NCIt 50 C4026
SNOMED-CT 68 254851009
UMLS 73 C0279665

Summaries for Ovarian Mucinous Cystadenocarcinoma

MalaCards based summary : Ovarian Mucinous Cystadenocarcinoma, also known as mucinous cystadenocarcinoma of ovary, is related to mucinous cystadenocarcinoma and cystadenocarcinoma. An important gene associated with Ovarian Mucinous Cystadenocarcinoma is FSHR (Follicle Stimulating Hormone Receptor), and among its related pathways/superpathways is Primary Focal Segmental Glomerulosclerosis FSGS. The drugs Carboplatin and Paclitaxel have been mentioned in the context of this disorder. Affiliated tissues include ovary, endothelial and liver, and related phenotypes are mortality/aging and reproductive system

Related Diseases for Ovarian Mucinous Cystadenocarcinoma

Diseases related to Ovarian Mucinous Cystadenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 20)
# Related Disease Score Top Affiliating Genes
1 mucinous cystadenocarcinoma 29.9 FSHR PCNA VIM
2 cystadenocarcinoma 10.7
3 cystic teratoma 10.2
4 teratoma 10.2
5 sarcoma 10.2
6 zollinger-ellison syndrome 10.1
7 pseudomyxoma peritonei 10.1
8 gelatinous ascites 10.1
9 choroiditis 9.9
10 endodermal sinus tumor 9.9
11 cervicitis 9.9
12 gingivitis 9.9
13 rhabdomyosarcoma 9.9
14 choriocarcinoma 9.9
15 endotheliitis 9.9
16 lymphangiomatosis 9.7 PCNA VIM
17 odontoma 9.7 PCNA VIM
18 endometrial stromal sarcoma 9.6 PCNA VIM
19 adenoid cystic carcinoma 9.5 PCNA VIM
20 meningioma, familial 9.2 PCNA VIM

Graphical network of the top 20 diseases related to Ovarian Mucinous Cystadenocarcinoma:



Diseases related to Ovarian Mucinous Cystadenocarcinoma

Symptoms & Phenotypes for Ovarian Mucinous Cystadenocarcinoma

MGI Mouse Phenotypes related to Ovarian Mucinous Cystadenocarcinoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 mortality/aging MP:0010768 9.35 FSHR ILF3 LMX1A PCNA VIM
2 reproductive system MP:0005389 8.92 FSHR LMX1A PCNA VIM

Drugs & Therapeutics for Ovarian Mucinous Cystadenocarcinoma

Drugs for Ovarian Mucinous Cystadenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 95)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Carboplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 41575-94-4 10339178 498142 38904
2
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
3
Bevacizumab Approved, Investigational Phase 3,Phase 1 216974-75-3
4
Cisplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 15663-27-1 84093 441203 2767
5
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
6
Capecitabine Approved, Investigational Phase 3,Phase 2,Phase 1 154361-50-9 60953
7
Oxaliplatin Approved, Investigational Phase 3,Phase 1 61825-94-3 5310940 9887054 43805 6857599
8
Mitoxantrone Approved, Investigational Phase 3 65271-80-9 4212
9
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Not Applicable 59-30-3 6037
10 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1
11 Antimitotic Agents Phase 3,Phase 2,Phase 1
12 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
13 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
14 Angiogenesis Inhibitors Phase 3,Phase 1
15 Angiogenesis Modulating Agents Phase 3,Phase 1
16 Antibodies Phase 3,Phase 1
17 Antibodies, Monoclonal Phase 3,Phase 1
18 Immunoglobulins Phase 3,Phase 1
19 Alkylating Agents Phase 3,Phase 2,Phase 1
20 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1
21 Antirheumatic Agents Phase 3,Phase 2,Phase 1
22 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
23 Endothelial Growth Factors Phase 3,Phase 1
24 Immunoglobulin G Phase 3,Phase 1
25 Mitogens Phase 3,Phase 1
26 Antimetabolites Phase 3,Phase 2,Phase 1
27 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
28 Analgesics Phase 3,Phase 1
29 Peripheral Nervous System Agents Phase 3,Phase 1,Not Applicable
30 Micronutrients Phase 3,Not Applicable
31 Trace Elements Phase 3,Not Applicable
32 Vitamin B Complex Phase 3,Not Applicable
33 Vitamins Phase 3,Not Applicable
34 Folate Nutraceutical Phase 3,Not Applicable
35 Vitamin B9 Nutraceutical Phase 3,Not Applicable
36
Doxorubicin Approved, Investigational Phase 2,Phase 1 23214-92-8 31703
37
Belinostat Approved, Investigational Phase 2 866323-14-0
38
Docetaxel Approved, Investigational Phase 1, Phase 2,Phase 2 114977-28-5 148124
39
Lenograstim Approved, Investigational Phase 2,Phase 1 135968-09-1
40
Topotecan Approved, Investigational Phase 2,Phase 1 119413-54-6, 123948-87-8 60700
41
Gemcitabine Approved Phase 2 95058-81-4 60750
42
Doxil Approved June 1999 Phase 2,Phase 1 31703
43 Anti-Bacterial Agents Phase 2,Phase 1
44 Antibiotics, Antitubercular Phase 2,Phase 1
45 Histone Deacetylase Inhibitors Phase 2
46
Erlotinib Hydrochloride Phase 2,Phase 1 183319-69-9 176871
47 Protein Kinase Inhibitors Phase 2,Phase 1
48 topoisomerase I inhibitors Phase 2,Phase 1
49 Adjuvants, Immunologic Phase 2,Phase 1
50 Anti-Infective Agents Phase 2

Interventional clinical trials:

(show top 50) (show all 54)
# Name Status NCT ID Phase Drugs
1 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Newly Diagnosed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer Completed NCT00483782 Phase 3 carboplatin;paclitaxel
2 Combination Chemotherapy With or Without Surgery in Treating Patients With Stage III Ovarian Epithelial Cancer Completed NCT00002568 Phase 3 cisplatin;paclitaxel
3 Paclitaxel and Cisplatin in Treating Patients With Stage III or Stage IV Ovarian Cancer or Primary Peritoneal Cancer Completed NCT00002717 Phase 3 cisplatin;paclitaxel
4 Combination Chemotherapy in Treating Patients With Primary Peritoneal or Stage III Epithelial Ovarian Cancer Completed NCT00003322 Phase 3 cisplatin;paclitaxel
5 Carboplatin Plus Paclitaxel With or Without Continued Low-Dose Paclitaxel in Treating Patients With Early-Stage Ovarian Cancer Completed NCT00003644 Phase 3 carboplatin;paclitaxel
6 Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer Active, not recruiting NCT01081262 Phase 3 Capecitabine;Carboplatin;Oxaliplatin;Paclitaxel
7 Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Active, not recruiting NCT00951496 Phase 3 Carboplatin;Carboplatin;Cisplatin;Paclitaxel;Paclitaxel
8 Paclitaxel Plus Carboplatin With or Without SCH-58500 in Treating Patients With Newly Diagnosed Stage III Ovarian or Stage III Primary Peritoneal Cancer Terminated NCT00003880 Phase 2, Phase 3 carboplatin;paclitaxel
9 Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Persistent Ovarian Epithelial Cancer Terminated NCT00002819 Phase 3 carboplatin;cyclophosphamide;mitoxantrone hydrochloride;paclitaxel
10 Acetyl-L-Carnitine Hydrochloride in Preventing Peripheral Neuropathy in Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing Chemotherapy Withdrawn NCT01492920 Phase 3
11 VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer Unknown status NCT01666444 Phase 2 pegylated liposomal doxorubicin (PLD);VTX-2337;Placebo
12 Combination Chemotherapy Plus IM-862 in Treating Patients With Resected Stage III Ovarian Cancer or Primary Peritoneal Cancer Unknown status NCT00017303 Phase 2 carboplatin;oglufanide disodium;paclitaxel
13 Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or Cisplatin Completed NCT00993616 Phase 2 belinostat;carboplatin
14 A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Completed NCT00939809 Phase 2
15 Sargramostim and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Previous Chemotherapy Completed NCT00466960 Phase 2 paclitaxel albumin-stabilized nanoparticle formulation
16 Erlotinib Plus Carboplatin and Paclitaxel in Ovarian Carcinoma Completed NCT00059787 Phase 2 paclitaxel;carboplatin;erlotinib
17 S0009 Combination Chemo and Surgery in Stage III or Stage IV Ovarian Cancer Completed NCT00008138 Phase 2 carboplatin;paclitaxel
18 Erlotinib, Docetaxel, and Carboplatin in Treating Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer Completed NCT00217529 Phase 1, Phase 2 carboplatin;docetaxel;erlotinib hydrochloride
19 Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Completed NCT00003944 Phase 2 carboplatin;cyclophosphamide;paclitaxel;topotecan hydrochloride
20 TLK286 in Treating Patients With Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Completed NCT00022347 Phase 2 canfosfamide hydrochloride
21 Laparoscopic Staging in Patients With Ovarian, Fallopian Tube, or Other Primary Abdominal Cancers Completed NCT00002538 Phase 2
22 Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Active, not recruiting NCT02101775 Phase 2 Adavosertib;Gemcitabine Hydrochloride
23 Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III Ovarian Cancer Terminated NCT00004221 Phase 2 Carboplatin;Cyclophosphamide;Paclitaxel;Topotecan Hydrochloride
24 Carboplatin, Paclitaxel, and Surgery in Treating Patients With Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer Terminated NCT00331422 Phase 2 carboplatin;paclitaxel
25 Docetaxel and Capecitabine in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cavity Cancer Terminated NCT00354601 Phase 2 capecitabine;docetaxel
26 TLR8 Agonist VTX-2337 and Pegylated Liposomal Doxorubicin Hydrochloride or Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer Completed NCT01294293 Phase 1 TLR8 Agonist VTX-2337;Pegylated Liposomal Doxorubicin Hydrochloride;Paclitaxel
27 Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Completed NCT01074411 Phase 1 Bortezomib;Carboplatin
28 Cisplatin and Paclitaxel in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer Completed NCT00814086 Phase 1 Paclitaxel;Cisplatin
29 Paclitaxel, Cisplatin, and Topotecan With or Without Filgrastim in Treating Patients With Newly Diagnosed Stage III or Stage IV Epithelial Ovarian Cancer Completed NCT00002913 Phase 1 paclitaxel;cisplatin;topotecan hydrochloride
30 Paclitaxel, Bevacizumab And Adjuvant Intraperitoneal Carboplatin in Treating Patients Who Had Initial Debulking Surgery for Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Completed NCT00079430 Phase 1 paclitaxel;carboplatin
31 Carboplatin and Paclitaxel With or Without Bevacizumab Compared to Docetaxel, Carboplatin, and Paclitaxel in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Carcinoma (Cancer) Completed NCT00085358 Phase 1 carboplatin;paclitaxel;docetaxel
32 Polyglutamate Paclitaxel and Carboplatin in Treating Patients With Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer Completed NCT00060359 Phase 1 Carboplatin;Paclitaxel Poliglumex
33 Liposomal Doxorubicin and Carboplatin in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Completed NCT00006235 Phase 1 carboplatin;pegylated liposomal doxorubicin hydrochloride
34 Combination Chemotherapy, Bone Marrow Transplantation, and Peripheral Stem Cell Transplantation in Treating Patients With Ovarian Epithelial Cancer Completed NCT00002600 Phase 1 carboplatin;cyclophosphamide
35 Topotecan Plus Etoposide in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer Completed NCT00003967 Phase 1 etoposide;topotecan hydrochloride
36 RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma Completed NCT00101972 Phase 1
37 Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cancer Completed NCT00005026 Phase 1 carboplatin;paclitaxel;topotecan hydrochloride
38 Melphalan and Thiotepa Followed by Peripheral Stem Cell Transplantation in Treating Patients With Epithelial Ovarian Cancer in Complete Remission Completed NCT00002977 Phase 1 melphalan;thiotepa
39 Gene Therapy in Treating Patients With Cancer Completed NCT00004178 Phase 1
40 Immunotoxin Therapy in Treating Patients With Advanced Cancer Completed NCT00006981 Phase 1
41 Combination Chemotherapy in Treating Patients With Untreated Ovarian, Peritoneal, or Fallopian Tube Cancer Completed NCT00003385 Phase 1 carboplatin;paclitaxel;pegylated liposomal doxorubicin hydrochloride
42 TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors Recruiting NCT02142803 Phase 1 Sapanisertib
43 Denileukin Diftitox Used in Treating Patients With Advanced Refractory Ovarian Cancer, Primary Peritoneal Carcinoma, or Epithelial Fallopian Tube Cancer Active, not recruiting NCT00357448 Phase 1
44 Recombinant Measles Virus Vaccine Therapy and Oncolytic Virus Therapy in Treating Patients With Progressive, Recurrent, or Refractory Ovarian Epithelial Cancer or Primary Peritoneal Cancer Active, not recruiting NCT00408590 Phase 1
45 Topotecan, High-Dose Cyclophosphamide, Carboplatin, and an Autologous Peripheral Blood Cell Transplant in Treating Patients With Recurrent Ovarian Cancer or Primary Peritoneal Cancer Active, not recruiting NCT00652691 Phase 1 carboplatin;cyclophosphamide;topotecan hydrochloride
46 Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors Terminated NCT01233505 Phase 1 veliparib;capecitabine;oxaliplatin
47 Liposomal Doxorubicin and Etoposide in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Peritoneal Cancer Terminated NCT00003380 Phase 1 etoposide;pegylated liposomal doxorubicin hydrochloride
48 Non Ivasive Prenatal Diagnosis (NIPD) of Cystic Fibrosis Unknown status NCT02130648
49 Laboratory Study in Predicting Tumor Response to Chemotherapy in Patients With Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Unknown status NCT00897039
50 Proteomic Profiling in Diagnosing Ovarian Cancer in Patients Who Are Undergoing Surgery for an Abnormal Pelvic Mass Unknown status NCT00238342 Not Applicable

Search NIH Clinical Center for Ovarian Mucinous Cystadenocarcinoma

Genetic Tests for Ovarian Mucinous Cystadenocarcinoma

Anatomical Context for Ovarian Mucinous Cystadenocarcinoma

MalaCards organs/tissues related to Ovarian Mucinous Cystadenocarcinoma:

41
Ovary, Endothelial, Liver, Brain, Bone Marrow, Bone, Skin

Publications for Ovarian Mucinous Cystadenocarcinoma

Articles related to Ovarian Mucinous Cystadenocarcinoma:

(show all 36)
# Title Authors Year
1
Co-Existing Ovarian Mucinous Cystadenocarcinoma with Mature Cystic Teratoma: A Rare Case Report. ( 29927186 )
2016
2
LMX1A as a prognostic marker in ovarian mucinous cystadenocarcinoma. ( 22586057 )
2012
3
Retraction. LMX1A as a prognostic marker in ovarian mucinous cystadenocarcinoma. ( 22706874 )
2012
4
Mucinous metaplasia of breast carcinoma with macrocystic transformation resembling ovarian mucinous cystadenocarcinoma in a case of synchronous bilateral infiltrating ductal carcinoma. ( 18801076 )
2008
5
Gingival metastasis from ovarian mucinous cystadenocarcinoma as an initial manifestation (a rare case report). ( 19246966 )
2008
6
An ovarian mucinous cystadenocarcinoma arising from mature cystic teratoma with para-aortic lymph node metastasis: a case report. ( 19471656 )
2008
7
Effects of antisense oligodeoxynucleotide to follicle-stimulating hormone receptor on the cell proliferation and apoptosis in cells derived from human ovarian mucinous cystadenocarcinoma in Vitro. ( 17393121 )
2007
8
Effects of antisense oligodeoxynucleotide to follicle-stimulating hormone receptor on the expression of proliferating cell nuclear antigen and vascular endothelial growth factor in primary culture cells derived from human ovarian mucinous cystadenocarcinoma. ( 16711022 )
2006
9
Anaplastic carcinoma arising in an ovarian mucinous cystadenocarcinoma in a 17-year-old female. ( 16472728 )
2006
10
Ovarian mucinous cystadenocarcinoma of low malignant potential associated with a mature cystic teratoma. ( 16951785 )
2006
11
Ovarian mucinous cystadenocarcinoma with mural nodule of anaplastic carcinoma and synchronous cervical squamous carcinoma. ( 15966336 )
2005
12
Ovarian mucinous cystadenocarcinoma of low malignant potential presented as a paraneoplastic skin lesion. ( 16234167 )
2005
13
Chemotherapy for ovarian mucinous cystadenocarcinoma during pregnancy: a case report. ( 15493185 )
2004
14
Choroidal metastases from a primary ovarian mucinous cystadenocarcinoma. ( 12707607 )
2003
15
Co-existent ovarian mucinous cystadenocarcinoma and ovarian choriocarcinoma. ( 12192487 )
2002
16
Ovarian mucinous cystadenocarcinoma with virilization. ( 11855891 )
2002
17
Virilization during pregnancy caused by ovarian mucinous cystadenocarcinoma. ( 11328230 )
2001
18
Ovarian mucinous cystadenocarcinoma as a cause of Zollinger-Ellison syndrome: report of a case and review of the literature. ( 10811352 )
2000
19
Ovarian mucinous cystadenocarcinoma with yolk sac tumor in a 71-year-old woman. ( 12090598 )
1999
20
Ovarian mucinous cystadenocarcinoma with malignant mural nodules. ( 9736414 )
1998
21
Ovarian mucinous cystadenocarcinoma with sarcoma-like mural nodules. ( 8624893 )
1996
22
Ovarian mucinous cystadenocarcinoma with sarcoma-like mural nodules. ( 7534853 )
1995
23
Establishment of OVS1 and OVS2 monoclonal antibodies recognizing human ovarian mucinous cystadenocarcinoma. ( 7488344 )
1995
24
Successful pregnancy in a patient with pseudomyxoma peritonei arising from ovarian mucinous cystadenocarcinoma treated with cisplatin. ( 8522263 )
1995
25
Cytogenetic changes in ovarian mucinous cystadenocarcinoma of low malignant potential with persistent pseudomyxoma peritonei. ( 7889512 )
1995
26
Ovarian mucinous cystadenocarcinoma with mural nodules of anaplastic carcinoma: report of a case and review of the literature. ( 8510201 )
1993
27
Ovarian mucinous cystadenocarcinoma with sarcoma-appearing mural nodule of anaplastic carcinoma. ( 8375741 )
1993
28
Rhabdomyosarcoma coexistent with ovarian mucinous cystadenocarcinoma: a case report. ( 1563909 )
1992
29
Ovarian mucinous cystadenocarcinoma producing alpha-fetoprotein. A case report. ( 1378991 )
1992
30
Immuno-histological characterization of OVS1 and OVS2 monoclonal antibodies recognizing human ovarian mucinous cystadenocarcinoma. ( 1284830 )
1992
31
Ovarian mucinous cystadenocarcinoma producing alpha-fetoprotein. ( 2456275 )
1988
32
Ovarian mucinous cystadenocarcinoma of low malignant potential associated with a mature cystic teratoma. ( 3338676 )
1988
33
Immunohistochemical and immunoelectron microscopic study of an amylase-producing, CA19-9 positive ovarian mucinous cystadenocarcinoma. ( 2455679 )
1988
34
Immunohistology of a sarcomatous mural nodule in an ovarian mucinous cystadenocarcinoma. ( 3429109 )
1987
35
Ovarian mucinous cystadenocarcinoma with mural nodule of carcinomatous derivation. A light and electron microscopic study. ( 6821801 )
1983
36
Zollinger-Ellison syndrome associated with ovarian mucinous cystadenocarcinoma. ( 1152863 )
1975

Variations for Ovarian Mucinous Cystadenocarcinoma

Expression for Ovarian Mucinous Cystadenocarcinoma

Search GEO for disease gene expression data for Ovarian Mucinous Cystadenocarcinoma.

Pathways for Ovarian Mucinous Cystadenocarcinoma

Pathways related to Ovarian Mucinous Cystadenocarcinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.49 PCNA VIM

GO Terms for Ovarian Mucinous Cystadenocarcinoma

Cellular components related to Ovarian Mucinous Cystadenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 ribonucleoprotein complex GO:1990904 8.62 ILF3 VIM

Biological processes related to Ovarian Mucinous Cystadenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 locomotory behavior GO:0007626 8.62 FSHR LMX1A

Molecular functions related to Ovarian Mucinous Cystadenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 double-stranded RNA binding GO:0003725 8.62 ILF3 VIM

Sources for Ovarian Mucinous Cystadenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....